Clinical symptom responses to atypical antipsychot...[Am J Psychiatry. 2008]

SearchDatabase nameforSearch term

Advanced Search

Warning: The NCBI web site requires JavaScript for full functionality. more...

Display Show

All: 1

Review: 0

Click to change filter selection through MyNCBI.

1: Am J Psychiatry. 2008 Jul;165(7):844-54. Epub 2008 Jun 2. Links

Comment in:: Am J Psychiatry. 2008 Jul;165(7):787-9.; Evid Based Ment Health. 2009 Feb;12(1):20.

Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.

Sultzer DL, Davis SM, Tariot PN, Dagerman KS, Lebowitz BD, Lyketsos CG, Rosenheck RA, Hsiao JK, Lieberman JA, Schneider LS; CATIE-AD Study Group.

Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA. dsultzer@ucla.edu

OBJECTIVE: The study measured the effects of atypical antipsychotics on psychiatric and behavioral symptoms in patients with Alzheimer's disease and psychosis or agitated behavior. METHOD: The Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer's Disease (CATIE-AD) Alzheimer's disease effectiveness study included 421 outpatients with Alzheimer's disease and psychosis or agitated/aggressive behavior. Patients were assigned randomly to masked, flexible-dose treatment with olanzapine, quetiapine, risperidone, or placebo for up to 36 weeks. Patients could be randomly reassigned to a different medication at the clinician's discretion, which ended phase 1. Psychiatric and behavioral symptoms, functioning, cognition, care needs, and quality of life were measured at regular intervals. RESULTS: In relation to placebo, the last observation in phase 1 showed greater improvement with olanzapine or risperidone on the Neuropsychiatric Inventory total score, risperidone on the Clinical Global Impression of Changes, olanzapine and risperidone on the Brief Psychiatric Rating Scale (BPRS) hostile suspiciousness factor, and risperidone on the BPRS psychosis factor. There was worsening with olanzapine on the BPRS withdrawn depression factor. Among patients continuing phase 1 treatment at 12 weeks, there were no significant differences between antipsychotics and placebo on cognition, functioning, care needs, or quality of life, except for worsened functioning with olanzapine compared to placebo. CONCLUSION: In this descriptive analysis of outpatients with Alzheimer's disease in usual care settings, some clinical symptoms improved with atypical antipsychotics. Antipsychotics may be more effective for particular symptoms, such as anger, aggression, and paranoid ideas. They do not appear to improve functioning, care needs, or quality of life.

PMID: 18519523 [PubMed - indexed for MEDLINE]

PMCID: PMC2714365

ReviewThe effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.
Cochrane Database Syst Rev. 2006 Jan 25; (1):CD003476. Epub 2006 Jan 25.

[Cochrane Database Syst Rev. 2006]
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
N Engl J Med. 2006 Oct 12; 355(15):1525-38.

[N Engl J Med. 2006]
A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease.
Clin Drug Investig. 2008; 28(5):291-303.

[Clin Drug Investig. 2008]
Atypical antipsychotics for the treatment of dementia-related behaviors: an update.
Med Health R I. 2007 Jun; 90(6):191-4.

[Med Health R I. 2007]
ReviewManagement of aggression, agitation, and psychosis in dementia: focus on atypical antipsychotics.
Am J Alzheimers Dis Other Demen. 2006 Mar-Apr; 21(2):101-8.

[Am J Alzheimers Dis Other Demen. 2006]
» See reviews... | » See all...

Cited by 1 PubMed Central article

ReviewCurrent treatments for sleep disturbances in individuals with dementia.
Deschenes CL, McCurry SM. Curr Psychiatry Rep. 2009 Feb; 11(1):20-6.

[Curr Psychiatry Rep. 2009]

Patient Drug Information

Risperidone (Risperdal®, Risperdal® M-TAB®)
Risperidone is used to treat the symptoms of schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions) in adults and teenagers 13 years of ...
Olanzapine (Zyprexa®, Zydis®, Symbyax® (as a combination product containing Olanzapine and Fluoxetine Hydrochloride))
Olanzapine is used to treat the symptoms of schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions). It is also used to treat bipolar dis...
Quetiapine (Seroquel®)
Quetiapine is used to treat the symptoms of schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions). It is also used to treat episodes of...
Source: AHFS Consumer Medication Information

Recent Activity

Clear Turn Off Turn On

Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: p...Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.
Informationist education.Informationist education.
bhagwat m AND (NIH[Affili...bhagwat m AND (NIH[Affiliation] OR Maryland[Affiliation] OR USDA[Affiliation] OR Methods Mol Biol.)(13)
AA[gr] OR NIAAA[gr] OR AG...AA[gr] OR NIAAA[gr] OR AG[gr] OR NIA[gr] OR AI[gr] OR AO[gr] OR NIAID[gr] OR AM[gr] OR NIADDK[gr] OR AR[gr] OR NIAMS[gr] OR AT[gr] OR NCCAM[gr] OR CA[gr] OR NCI[gr] OR CO[gr] OR BC[gr] OR PC[gr] OR SC[gr] OR CN[gr] OR CB[gr] OR CP[gr] OR CM[gr] OR CL[gr] OR CLC[gr] OR CT[gr] OR CIT[gr] OR DA[gr] OR NIDA[gr] OR DC[gr] OR NIDCD[gr] OR DE[gr] OR NIDCR[gr] OR DK[gr] OR NIDDK[gr] OR DS[gr] OR ES[gr] OR NIEHS[gr] OR EY[gr] OR NEI[gr] OR GM[gr] OR NIGMS[gr] OR HD[gr] OR NICHD[gr] OR HG[gr] OR NHGRI[gr] OR HL[gr] OR NHLBI[gr] OR HV[gr] OR HB[gr] OR HR[gr] OR HI[gr] OR HO[gr] OR HC[gr] OR LM[gr] OR NLM[gr] OR MH[gr] OR NIMH[gr] OR NR[gr] OR NINR[gr] OR NS[gr] OR NINDS[gr] OR OD[gr] OR GF[gr] OR JT[gr] OR NIH[gr] OR ORS[gr] OR RG[gr] OR CSR[gr] OR RR[gr] OR NCRR[gr] OR RS[gr] OR DRS[gr] OR RC[gr] OR CCR[gr] OR TW[gr] OR FIC[gr] OR WH[gr] OR WHI[gr] OR WTEP[gr] OR MD[gr] OR NCMHD[gr] OR EB[gr] OR NIBIB[gr] OR GW[gr] OR GAS[gr] OR NB[gr] OR OF[gr] OR ORFDO[gr] OR OL[gr] OR OLAO[gr] OR RM[gr] OR RMOD[gr] OR SF[gr] OR SBRP[gr] OR Research Support, N.I.H., Extramural[pt] OR Research Support, N.I.H., Intramural[pt](1452760)
Patterns of growth in verbal abilities among children with autism spectrum disorder.Patterns of growth in verbal abilities among children with autism spectrum disorder.

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

» See more...

Display Show

Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.

Related articles

Cited by 1 PubMed Central article

Patient Drug Information

Recent Activity